Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Individualizing RCC treatment

Martin Voss • 16 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer

Martin Voss, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses updates on the progression towards individualizing therapy for metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Martin Voss

Biomarkers in RCC
2:01
Biomarkers in RCC
Martin Voss • 16 Feb 2020
JAVELIN Renal 101: DepOR & outcomes in RCC
2:14
JAVELIN Renal 101: DepOR & outcomes in RCC
Martin Voss • 16 Feb 2020

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals